Dynorphin A, an endogenous neuropeptide, is has high affinity and selectivity for the kappa opioid receptors. It has been reported that the N-terminus ?message? sequence is important for kappa opioid receptor activation while the ?address? sequence is designated as the potency-enhancing domain responsible for the high specificity of dynorphin A. Two novel lead Dyn A analogues, arodyn (aromatic dynorphin), and JVA-901, have displayed different structure-activity relationships from Dyn A. It is therefore hypothesized that arodyn and JVA-901 bind differently to the kappa opioid receptors. The goal of this research proposal is to identify potent and selective kappa opioid receptor antagonists. To pursue this goal novel selective kappa receptor antagonists will be designed utilizing classic and combinatorial peptide libraries and evaluated using Chinese hamster ovary cells stably expressing opioid receptors. The combination of classical and combinatorial approaches will be used to modify the sequences of the two aforementioned lead peptides and generate focused peptide libraries. Combinatorial peptide libraries offer the advantage of synthesizing a variety of peptides simultaneously and allows the introduction of various combinations of amino acids in the sequence of arodyn and JVA-901. Syntheses will be done using solid phase peptide synthesis. There are many potential clinical applications of kappa agonists and antagonists, including the prevention of pancreatitis, neuroprotection (epilepsy) and anti-convulsants, potential treatment in cocaine abuse and opioid dependence as well as use in pharmacological assays as pharmacological tools to help understand kappa receptor-ligand interactions at the molecular level since kappa-selective peptide antagonists are limited.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Predoctoral Individual National Research Service Award (F31)
Project #
1F31DA015029-01
Application #
6450635
Study Section
Special Emphasis Panel (ZRG1-CDF-6 (20))
Program Officer
Babecki, Beth
Project Start
2001-10-01
Project End
Budget Start
2001-10-01
Budget End
2002-09-30
Support Year
1
Fiscal Year
2001
Total Cost
$20,034
Indirect Cost
Name
University of Maryland Baltimore
Department
Other Health Professions
Type
Schools of Pharmacy
DUNS #
003255213
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Bennett, M A; Murray, T F; Aldrich, J V (2005) Structure-activity relationships of arodyn, a novel acetylated kappa opioid receptor antagonist. J Pept Res 65:322-32
Bennett, Marco A; Murray, Thomas F; Aldrich, Jane V (2002) Identification of arodyn, a novel acetylated dynorphin A-(1-11) analogue, as a kappa opioid receptor antagonist. J Med Chem 45:5617-9